SK Biopharm gets approval for sleep disorder drugA biopharmaceutical affiliate of Korea’s SK Group said Thursday that it has won sales approval from the U.S. Food and Drug Administration (FDA) for its sleep disorder drug.
The product, named Solriamfetol, is the country’s first indigenous drug for the central nervous system to receive the green light from the FDA, SK Biopharmaceuticals said.
“This FDA approval is the result of SK Biopharm’s efforts to develop new drugs for the central nervous system,” CEO Cho Jeong-woo said in a press release.
More in Industry
Luxury loungewear is no longer just for lounging
KGC to work on a ginseng-based vaccine adjuvant
Hanwha Techwin continues selling CCTV systems overseas
Popeyes to close all branches in Korea this month
Contract signed for Covid-19 vaccine